Appendix B: Drug Characteristics Tables
Appendix B, Table 1. Coformulated and Copackaged Antiretroviral Regimens
The following table includes dose recommendations for Food and Drug Administration (FDA)-approved coformulated and copackaged antiretroviral regimens. Please see the class-specific drug characteristics tables (Appendix B, Tables 3, 4, 5, and 6) for details about the individual drugs included in these products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The products in this table are listed by drug class and arranged in alphabetical order by trade name within each class.
Trade Name (Abbreviations) |
ARV Drugs Included in the Regimen | Dosing Recommendationa |
---|---|---|
INSTI plus Two NRTIs | ||
Biktarvy (BIC/TAF/FTC) |
Bictegravir 50 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg | One tablet PO once daily |
Genvoya (EVG/c/TAF/FTC) |
Elvitegravir 150 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg | One tablet PO once daily with food |
Stribild (EVG/c/TDF/FTC) |
Elvitegravir 150 mg/cobicistat 150 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily with food |
Triumeq (DTG/ABC/3TC) |
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg | One tablet PO once daily |
INSTI plus One NRTI | ||
Dovato (DTG/3TC) |
Dolutegravir 50 mg/lamivudine 300 mg | One tablet PO once daily |
PI plus Two NRTIs | ||
Symtuza (DRV/c/TAF/FTC) |
Darunavir 800 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg | One tablet PO once daily with food |
NNRTI plus Two NRTIs | ||
Atripla (EFV/TDF/FTC) |
Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily on an empty stomach, preferably at bedtime |
Complera (RPV/TDF/FTC) |
Rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily with a meal |
Delstrigo (DOR/TDF/3TC) |
Doravirine 100 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily |
Odefsey (RPV/TAF/FTC) |
Rilpivirine 25 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg | One tablet PO once daily with a meal |
Symfi (EFV/TDF/3TC) |
Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily on an empty stomach, preferably at bedtime |
Symfi Lo (EFV/TDF/3TC) |
Efavirenz 400 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily on an empty stomach, preferably at bedtime |
INSTI plus One NNRTI | ||
Cabenuva (CAB IM and RPV IM) |
Cabenuva 600 mg/900 mg kit contains:
Cabenuva 400 mg/600 mg kit contains:
|
Lead-in with Oral CAB and RPV:
IM CAB and RPV:
|
Juluca (DTG/RPV) |
Dolutegravir 50 mg/rilpivirine 25 mg | One tablet PO once daily with a meal |
a For dose adjustments in patients with renal or hepatic insufficiency, see Appendix B, Table 11 When no food restriction is listed, the product can be taken with or without food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = orally; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate |
Appendix B: Drug Characteristics Tables
Appendix B, Table 1. Coformulated and Copackaged Antiretroviral Regimens
The following table includes dose recommendations for Food and Drug Administration (FDA)-approved coformulated and copackaged antiretroviral regimens. Please see the class-specific drug characteristics tables (Appendix B, Tables 3, 4, 5, and 6) for details about the individual drugs included in these products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The products in this table are listed by drug class and arranged in alphabetical order by trade name within each class.
Trade Name (Abbreviations) |
ARV Drugs Included in the Regimen | Dosing Recommendationa |
---|---|---|
INSTI plus Two NRTIs | ||
Biktarvy (BIC/TAF/FTC) |
Bictegravir 50 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg | One tablet PO once daily |
Genvoya (EVG/c/TAF/FTC) |
Elvitegravir 150 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg | One tablet PO once daily with food |
Stribild (EVG/c/TDF/FTC) |
Elvitegravir 150 mg/cobicistat 150 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily with food |
Triumeq (DTG/ABC/3TC) |
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg | One tablet PO once daily |
INSTI plus One NRTI | ||
Dovato (DTG/3TC) |
Dolutegravir 50 mg/lamivudine 300 mg | One tablet PO once daily |
PI plus Two NRTIs | ||
Symtuza (DRV/c/TAF/FTC) |
Darunavir 800 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg | One tablet PO once daily with food |
NNRTI plus Two NRTIs | ||
Atripla (EFV/TDF/FTC) |
Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily on an empty stomach, preferably at bedtime |
Complera (RPV/TDF/FTC) |
Rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily with a meal |
Delstrigo (DOR/TDF/3TC) |
Doravirine 100 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily |
Odefsey (RPV/TAF/FTC) |
Rilpivirine 25 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg | One tablet PO once daily with a meal |
Symfi (EFV/TDF/3TC) |
Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily on an empty stomach, preferably at bedtime |
Symfi Lo (EFV/TDF/3TC) |
Efavirenz 400 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily on an empty stomach, preferably at bedtime |
INSTI plus One NNRTI | ||
Cabenuva (CAB IM and RPV IM) |
Cabenuva 600 mg/900 mg kit contains:
Cabenuva 400 mg/600 mg kit contains:
|
Lead-in with Oral CAB and RPV:
IM CAB and RPV:
|
Juluca (DTG/RPV) |
Dolutegravir 50 mg/rilpivirine 25 mg | One tablet PO once daily with a meal |
a For dose adjustments in patients with renal or hepatic insufficiency, see Appendix B, Table 11 When no food restriction is listed, the product can be taken with or without food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = orally; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate |
Download Guidelines
- Section OnlyPDF (261.29 KB)
- Full GuidelinePDF (5.07 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)